The views and opinions expressed in this editorial article are those of the author and do not reflect the official policy or position of Salina Post or Eagle Media. The editorial is intended to stimulate critical thinking and debate on issues of public interest and should be read with an open mind. Readers are encouraged to consider multiple sources of information and to form their own informed opinions.
By: JAY VANIER
The 340B drug pricing program was created with a good purpose: helping certain hospitals and clinics buy outpatient drugs at discounted prices so they could stretch limited resources and serve vulnerable patients. That mission sounds worthy, especially in rural states like Kansas. But the real question today is not whether 340B began with good intentions. The question is whether the program, as it operates now, is doing what Kansans think it is doing.
That is why the debate in Topeka matters.
Critics have framed this as a fight over whether House leadership should have allowed more open floor debate on Senate Bill 284. Floor debate does matter. Kansans deserve to hear arguments in public and see where their representatives stand. But that was never the only issue. The larger question was whether Kansas should move forward with stronger protections for 340B before lawmakers first secured more transparency about how the program’s financial benefits arebeing used.
That was the purpose of House Bill 2550.
HB 2550 was a transparency bill. It would have required Kansas hospitals participating in 340B to file annual reports with the Kansas Department of Insurance, and those reports would have been made public online. The bill called for disclosures on how hospitals use 340B savings, what those savings amount to, what they spend on drugs, what they receive in payment, and what they pay to contract pharmacies and others administering the program.
That is not an attack on rural hospitals. It is not an attack on patients. It is a basic accountability measure.
Supporters called HB 2550 a thoughtful and measured transparency bill. Opponents, including hospital groups, argued it was duplicative and burdensome. That is a fair debate to have. But the public still has a right to know whether a program this large and politically protected is functioning as promised.
And there is good reason to ask.
Kansas legislative materials have explained that 340B allows eligible entities to buy drugs at discounted prices, keep the difference between acquisition cost and insurance reimbursement, and then use that revenue broadly because federal law generally does not restrict how covered entities spend it. In plain English, that means the savings do not have to be passed directly to patients in a clear, traceable way.
That concern has only grown. Lawmakers studying the issue heard testimony that 340B has drifted from a low-income drug savings tool into what critics described as an “arbitrage system,” with weak guardrails and incentives that can reward hospitals, contract pharmacies, and PBMs without
clearly showing patient benefit. The same legislative review noted that Kansas 340B hospitals had 1,123 pharmacy contracts, and 59 percent of them were out of state.
Against that backdrop, the Legislature was also considering SB 284, the “Defense of Drug Delivery Act,” which would prohibit manufacturer interference with 340B drug distribution. So lawmakers were facing two questions at once: Should Kansas protect the mechanics of 340B, and should it demand proof that the program’s financial benefits are really helping patients the way the public expects?
That distinction matters.
House Speaker Dan Hawkins has taken criticism for slowing SB 284. But if his position was that Kansas should not rush to protect the machinery of 340B before resolving the transparency issue, that is not anti-patient or anti-rural. That is a defensible position grounded in oversight.
HB 2550 had a hearing but did not advance. SB 284 stayed alive and kept moving through committees. Critics say that means Hawkins was blocking the bill. Perhaps that was the practical result. But even so, it is more accurate to say he was insisting on accountability before granting further protection.
That is not obstruction. That is judgment.
A program can begin with a noble purpose and still grow into something sprawling, opaque, and difficult to defend. Kansas should support patients. Kansas should support rural providers. But Kansas should not blindly defend 340B without demanding proof.
If 340B is working, transparency will strengthen it. If it is not, reform is overdue. Either way, Kansans deserve answers first.
You can send us your opinions/letters to the editor, along with your name, city and or county location to newstips@salinapost.com